Literature DB >> 11568742

Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996.

R B Harris1, K Griffith, T E Moon.   

Abstract

This report describes trends in the incidence of various nonmelanoma skin cancers in a region of high ultraviolet exposure. The Southeastern Arizona Skin Cancer Registry routinely identified cases of skin cancer between 1985 and 1996 through pathology logs and reports from dermatology offices and laboratories in 3 Arizona counties. The incidence rates for squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) for non-Hispanic whites were 3 to 6 times higher than the incidence rates from more northern regions. The rates for non-Hispanic whites were approximately 11 times greater than rates for Hispanics. Furthermore, there was no constant increase in the incidence of nonmelanoma skin cancers. The incidence of SCC, in particular, demonstrated a plateau or even a modest decline between 1985 and 1996. Thus the incidence rates of both SCC and BCC in Arizona, although among the highest in the world, do not appear to be increasing as rapidly as predicted elsewhere.

Entities:  

Mesh:

Year:  2001        PMID: 11568742     DOI: 10.1067/mjd.2001.114742

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  27 in total

1.  Mediating variables in a parent based intervention to reduce skin cancer risk in children.

Authors:  Rob Turrisi; Joel Hillhouse; June K Robinson; Jerod Stapleton
Journal:  J Behav Med       Date:  2007-04-24

Review 2.  An Analysis of Laser Therapy for the Treatment of Nonmelanoma Skin Cancer.

Authors:  Teo Soleymani; Michael Abrouk; Kristen M Kelly
Journal:  Dermatol Surg       Date:  2017-05       Impact factor: 3.398

3.  Association of CRR9 locus with elevated risk of squamous cell carcinoma and basal cell carcinoma.

Authors:  Tao Liu; Li Jiang; Xiaoxing Lv; Jinqing Li; Yuejun Li; Wangzhou Li; Xueyong Li; Jing Li
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin.

Authors:  Yira Bermudez; Steven P Stratton; Clara Curiel-Lewandrowski; James Warneke; Chengcheng Hu; George T Bowden; Sally E Dickinson; Zigang Dong; Ann M Bode; Kathylynn Saboda; Christine A Brooks; Emanuel F Petricoin; Craig A Hurst; David S Alberts; Janine G Einspahr
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-01

5.  Invasive cutaneous squamous cell carcinoma incidence in US health care workers.

Authors:  Khang D Nguyen; Jiali Han; Tricia Li; Abrar A Qureshi
Journal:  Arch Dermatol Res       Date:  2014-05-28       Impact factor: 3.017

6.  Staged-surgery with permanent pathology for the management of high-risk nonmelanoma skin cancer of the nose.

Authors:  Görkem Eskiizmir; Gülsüm Gençoğlan; Peyker Temiz; Zafer Hirçin; Aylin Ermertcan
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-08       Impact factor: 2.503

7.  Basal-cell carcinoma incidence and associated risk factors in U.S. women and men.

Authors:  Shaowei Wu; Jiali Han; Wen-Qing Li; Tricia Li; Abrar A Qureshi
Journal:  Am J Epidemiol       Date:  2013-07-04       Impact factor: 4.897

8.  [Changes in treatment of squamous cell carcinoma over time. A process analysis].

Authors:  C Rogalski; G Gelbrich; R Renner; K Hebestreit; U Paasch
Journal:  Hautarzt       Date:  2009-09       Impact factor: 0.751

9.  Clinical and histopathologic characteristics of skin malignancies in Qassim Region, Saudi Arabia.

Authors:  Abdullateef A Alzolibani; Hani A Al Shobaili; Ahmad Al Robaee; Athar Khan; Imran Ul Haque; Nagendra Seethapathi Rao; Abdulaziz Alrejaie
Journal:  Int J Health Sci (Qassim)       Date:  2013-01

10.  Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.

Authors:  G R Burmester; P Mease; B A C Dijkmans; K Gordon; D Lovell; R Panaccione; J Perez; A L Pangan
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.